Biggest Opportunity: The biggest opportunity to unlock in our sector of the life-sciences community is patient empowerment. Early phase drug development has a cascading effect across the rest of the pharma life cycle, even the smallest strategic decisions having significant, potentially multi-billion dollar consequences further downstream. By circumventing the traditional communication roadblocks between pharma companies and patients through influential, well-informed, and trustworthy patient ambassadors, the industry has an unprecedented opportunity to listen and integrate end user insights like never before. Therapeutics that otherwise might not be considered — and others that shouldn’t be — can stand the test of patient input. And clinical trials, often stubbornly resistant to change and challenged by a paucity of qualified subjects and alarmingly low retention, may finally flourish thanks to patients guiding and motivating other patients to better understand and enthusiastically participate in them.

Read the article at https://www.pharmavoice.com/digital-edition/nov-dec-2021#21